TRACCAR T cells were robustly detected at the CD22(+) tumor site (left flank) but were almost absent from the CD22(-) tumor site (right flank, Fig. 5b, left graph), indicating that TRACCAR T cells preferentially accumulate at their intended tumor-specific site. This evidence concerns the gene CD22 and neoplasm.